Literature DB >> 2948730

Comparison of 5-FU versus FUDR activity in human colorectal cancer using an in vitro clonogenic assay (HTCA).

M Flentje, D Flentje, P Schlag.   

Abstract

Comparative in vitro drug testing was performed in 72 of 183 surgically removed human colorectal cancer specimens (34 primary lesions, 38 metastases). In 10 of these tumors, comparative dose-response curves were obtained. Given a greater than or equal to 70% ICF (inhibition of colony formation) as threshold for in vitro sensitivity, 5-FU was active in 16/62 specimens, and FUDR in 14/62. Significantly discordant sensitivity results were observed in 8/62 tests, 5-FU being the more active agent in 5 of these cases. These data are supported by the finding of 3 considerably differing dose-response curves in 10 additional comparative studies of human primary tumors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2948730     DOI: 10.1007/bf00273390

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

1.  PYRIMIDINE METABOLISM IN TISSUE CULTURE CELLS DERIVED FROM RAT HEPATOMAS. I. SUSPENSION CELL CULTURES DERIVED FROM THE NOVIKOFF HEPATOMA.

Authors:  P A MORSE; V R POTTER
Journal:  Cancer Res       Date:  1965-05       Impact factor: 12.701

2.  Studies on fluorinated pyrimidines. XI. In vitro studies on tumor resistance.

Authors:  C HEIDELBERGER; G KALDOR; K L MUKHERJEE; P B DANNEBERG
Journal:  Cancer Res       Date:  1960-07       Impact factor: 12.701

3.  A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil.

Authors:  W D Ensminger; A Rosowsky; V Raso; D C Levin; M Glode; S Come; G Steele; E Frei
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

Review 4.  Chemotherapy of gastrointestinal cancer.

Authors:  C G Moertel
Journal:  N Engl J Med       Date:  1978-11-09       Impact factor: 91.245

5.  Comparative studies of fluorinated pyrimidines with various cell lines.

Authors:  M Umeda; C Heidelberger
Journal:  Cancer Res       Date:  1968-12       Impact factor: 12.701

6.  Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture.

Authors:  J D Laskin; R M Evans; H K Slocum; D Burke; M T Hakala
Journal:  Cancer Res       Date:  1979-02       Impact factor: 12.701

Review 7.  Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture.

Authors:  G Weber
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

8.  Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations.

Authors:  C A Bertelsen; V K Sondak; B D Mann; E L Korn; D H Kern
Journal:  Cancer       Date:  1984-03-15       Impact factor: 6.860

9.  Prospective clinical trial of a human tumor cloning system.

Authors:  D D Von Hoff; G M Clark; B J Stogdill; M F Sarosdy; M T O'Brien; J T Casper; D E Mattox; C P Page; A B Cruz; J F Sandbach
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

10.  Evaluation of single-agent therapy in human colorectal tumour xenografts.

Authors:  P J Houghton; J A Houghton
Journal:  Br J Cancer       Date:  1978-05       Impact factor: 7.640

View more
  2 in total

1.  Immunotargeting of daunomycin to localized and metastatic human colon adenocarcinoma in athymic mice.

Authors:  E Hurwitz; R Adler; D Shouval; H Takahashi; J R Wands; M Sela
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  In vitro study on intrathecal use of 5-fluoro-2'-deoxyuridine (FdUrd) for meningeal dissemination of malignant brain tumors.

Authors:  M Yamada; H Nakagawa; M Fukushima; K Shimizu; T Hayakawa; K Ikenaka
Journal:  J Neurooncol       Date:  1998-04       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.